Prostate Cancer Genomic Test Predicts Therapy Benefit
A new genomic classifier helps identify prostate cancer patients most likely to see a reduction in metastasis from hormone therapy.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Should genomic testing guide whether patients receive intensive cancer treatments?
A 22-gene genomic classifier can help predict which prostate cancer patients benefit most from short-term androgen deprivation therapy. This retrospective analysis of the phase 3 NRG/RTOG 0815 trial identifies a clear distinction in treatment outcomes based on genomic risk scores.
Why it matters
Distinguishing between patients who benefit from treatment intensification and those who do not helps avoid unnecessary therapy. This tool could refine personalized care by focusing aggressive treatment on patients whose tumor biology suggests a higher likelihood of responding to hormone therapy.
In an analysis of 395 prostate biopsy specimens from a phase 3 trial with a median follow-up of 10.2 years, researchers found that high-risk genomic scores were independently associated with distant metastasis. These findings remain preliminary pending prospective validation.
The players
NRG Oncology
A non-profit research organization that conducts multi-institutional clinical trials in gynecologic, gastrointestinal, and genitourinary cancers.
ASTRO
The American Society for Radiation Oncology, which hosts annual meetings to present major clinical trial outcomes in oncology.
The details
The Decipher genomic classifier profiles tumor tissue to categorize patients into low, intermediate, or high-risk groups based on their biological signatures. Researchers performed a multivariable analysis adjusting for age, clinical risk factors, and radiation modality to isolate the impact of genomic scores on treatment response. High genomic risk scores correlated with a significantly higher risk of biochemical failure and distant metastasis, suggesting that specific tumor biology dictates the efficacy of hormonal intervention.
Timeline
2026: The NRG-GU010 phase 3 trial completed enrollment.
September 29, 2026: Results were presented at the ASTRO annual meeting in Boston.
Health Landscape
This analysis builds on the data from the phase 3 NRG/RTOG 0815 trial to refine personalized medicine in oncology. It highlights a move toward biomarker-driven treatment strategies designed to optimize the balance between therapeutic benefits and the side effects of hormone therapy.
If you are considering androgen deprivation therapy, the use of genomic classifiers is an area worth discussing with your radiation oncologist or urologist. Ask your care team whether genomic profiling of your tumor could provide clarity on whether intensive hormone therapy is necessary.
The takeaway
Genomic profiling may help tailor prostate cancer treatment by identifying patients who truly benefit from additional hormone therapy. Discuss with your physician whether biomarker testing is appropriate for your specific clinical stage and pathology.
Further reading
For more information on current treatment standards, visit Cancer.
Source note: This article includes information reported by Oncology Nurse Advisor.
Live Poll
Should genomic testing guide whether patients receive intensive cancer treatments?
